Cargando…
Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia
Objective: Patients with Multiple Sclerosis (MS) and on disease modifying therapies (DMTs) that can be immunosuppressive or immunomodulatory form a special group where risk of continuation of DMT needs to be taken into account with risk of contracting Covid-19. This concept can pose a degree of anxi...
Autores principales: | Seery, Nabil, Li, Vivien, Nguyen, Ai-Lan, Roos, Izanne, Buzzard, Katherine A, Atvars, Roberts, Taylor, Nicola, Tunnell, Kelsey, Carey, John, Dwyer, Chris, Taylor, Hasini Fernandoa Lisa, Baker, Josephine, Marriott, Mark P, Kilpatrick, Trevor J, Kalincik, Tomas, Monif, Mastura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493747/ https://www.ncbi.nlm.nih.gov/pubmed/32957057 http://dx.doi.org/10.1016/j.msard.2020.102516 |
Ejemplares similares
-
Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study
por: Seery, Nabil, et al.
Publicado: (2021) -
Impact of telehealth on health care in a multiple sclerosis outpatient clinic during the COVID-19 pandemic
por: Li, Vivien, et al.
Publicado: (2022) -
COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls
por: Longinetti, Elisa, et al.
Publicado: (2022) -
Observational studies of treatment effectiveness in neurology
por: Kalincik, Tomas, et al.
Publicado: (2023) -
The prevalence of epileptic seizures in multiple sclerosis in a large
tertiary hospital in Australia
por: Ooi, Suyi, et al.
Publicado: (2021)